A multicenter, phase 2, open-label study evaluating efficacy, safety, tolerability, and PK of AMG 193 in subjects with metastatic or locally advanced MTAP-deleted NSCLC who have previously received at least one line of treatment.

This study will be conducted in 2 parts:

• Part 1 will evaluate 2 active dose levels of AMG 193. Subjects will be randomized to either the target dose of 800 mg or 1200 mg of AMG 193 administered oral daily continuously in 28-day cycles.
• Part 2 will be a dose expansion phase for 1 or both doses. Part 2 will continue to enroll up to approximately 100 subjects per dose level (with Part 1 and Part 2 combined).

• Performance Status ≤ 1 and histologically or cytologically confirmed metastatic or unresectable locally advanced MTAP-deleted non-small cell lung cancer.
• Subjects must have progressed after receiving platinum-based doublet chemotherapy and a checkpoint inhibitor (unless contraindicated).
• Subjects with stable treated brain metastases or untreated asymptomatic brain metastases ≤ 2 cm in size per lesion are eligible.

• Subjects with tumors harboring the following mutations amenable to targeted therapies will be excluded: epidermal growth factor receptor (EGFR) / ALK receptor tyrosine kinase (ALK) / ROS proto-oncogene 1 (ROS1) / neurotrophic tyrosine receptor kinase (NTRK) / MET proto-oncogene (MET) / B-Raf proto-oncogene (BRAF)/ RET proto oncogene (RET) / Human epidermal growth factor receptor 2 (HER2) / KRAS proto oncogene (KRAS).